Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial by Matucci-Cerinic, Marco et al.
Extended report
Ann Rheum Dis 2011;70:32–38. doi:10.1136/ard.2010.130658 32
  For numbered afﬁ  liations see 
end of article 
    Correspondence  to   
Marco Matucci-Cerinic, AOUC 
Department of Biomedicine, 
Division of Rheumatology, 
DENOTHE Center, University of 
Florence, Villa Monna Tessa, 
Viale Pieraccini 18, 50139 
Florence, Italy; 
cerinic@uniﬁ   .it                               
Accepted 4 July 2010
Published Online First 
28 September 2010
  ABSTRACT 
  Objectives      Ischaemic digital ulcers (DUs) are common 
in patients with systemic sclerosis (SSc) and are a cause 
of disease-related morbidity. In an earlier trial, treatment 
with bosentan, an oral endothelin receptor antagonist, 
reduced the occurrence of new DUs by 48%. The present 
study (RAPIDS-2, for ‘RAndomized, double-blind, Placebo-
controlled study with bosentan on healing and prevention 
of Ischemic Digital ulcers in patients with systemic 
Sclerosis’) was conducted to more fully evaluate the 
effects of bosentan treatment on DUs associated with 
SSc.  
  Methods      This double-blind, placebo-controlled trial 
conducted at 41 centres in Europe and North America 
randomised 188 patients with SSc with at least 1 active 
DU (‘cardinal ulcer’) to bosentan 62.5 mg twice daily for 
4 weeks and 125 mg twice daily thereafter for 20 weeks 
(n=98) or matching placebo (n=90; total 24 weeks). 
The two primary end points were the number of new DUs 
and the time to healing of the cardinal ulcer. Secondary 
end points included pain, disability and safety.   
  Results      Over 24 weeks, bosentan treatment was 
associated with a 30% reduction in the number of new 
DUs compared with placebo (mean±standard error: 
1.9±0.2 vs 2.7±0.3 new ulcers; p=0.04). This effect 
was greater in patients who entered the trial with more 
DUs. There was no difference between treatments in 
healing rate of the cardinal ulcer or secondary end points 
of pain and disability. Peripheral oedema and elevated 
aminotransferases were associated with bosentan 
treatment.  
  Conclusions      Bosentan treatment reduced the 
occurrence of new DUs in patients with SSc but had no 
effect on DU healing. Bosentan was well tolerated and 
may be a useful adjunct in the management of patients 
with  SSc  with  recurrent  DUs.      
  INTRODUCTION 
  Intimal hyperplasia, endothelial dysfunction and 
occlusive vasculopathy are ubiquitous features of 
systemic sclerosis (SSc). These vascular lesions are 
the underlying basis of important clinical syndromes 
in SSc, including scleroderma renal crisis, pulmo-
nary arterial hypertension (PAH) and Raynaud’s 
phenomenon.    1    Patients with SSc are at high risk for 
the development of ischaemic digital ulcers (DUs), 
which occur in 35% to 60% of patients with SSc    2     –      5    
and are an important source of morbidity. Among a 
cohort of 2080 patients with SSc identiﬁ  ed between 
1972 and 1995 and prospectively followed-up for a 
mean of 10 years, 58% of patients had a history of 
DUs.    5    Of all patients with SSc, 32% (666 patients) 
had persistent or recurrent DUs for ≥6 months; of 
these, 30% (197 patients) had severe DUs (compli-
cated by gangrene, or requiring digital sympathec-
tomy or amputation). In one series, the incidence 
of ﬁ  nger amputation as a consequence of DUs was 
1.2% per patient-year.    6    
  The pathogenesis of DUs is thought to include 
many of the hallmark processes of critical tissue 
ischaemia, such as impaired afferent vasomotion, 
microvascular disruption, reduced venous drainage, 
increased local platelet activation and increased leu-
cocyte adherence.    1    As a result, no single pharma-
cological treatment is entirely effective. Nifedipine 
and intravenous iloprost reduced the frequency 
and severity of SSc-related Raynaud’s phenomenon 
attacks,    7    and iloprost was shown to improve DU 
healing in another trial that included patients with 
active DUs.    8    Few studies have been speciﬁ  cally 
designed to examine efﬁ   cacy in the prevention 
or treatment of DUs. Nifedipine and intravenous 
iloprost resulted in the reduction from baseline 
in the mean number of DUs in a small study.    7    
Similarly, a trial in patients with severe PAH associ-
ated with SSc    9    indicated there may be a beneﬁ  cial 
effect of epoprostenol on the number of DUs. In 
a recent small placebo-controlled study, atorvas-
tatin reduced the number of new DUs in associa-
tion with improvement in markers of endothelial 
function.    10    
  Indirect evidence implicates endothelin (ET) as 
a potential mediator of the vascular dysfunction 
in SSc. Plasma ET concentrations are increased 
in patients with SSc, and there is evidence for 
increased ET  B   receptor expression in lung, skin and 
blood vessels in this disease.    11    Other actions of ET 
relevant to SSc include proinﬂ  ammatory and prolif-
erative effects as well as mediation of vasoconstric-
tion.    12    ET receptor antagonists including bosentan 
are now commonly used for the treatment of PAH 
in SSc.    13     –      15    
  A previous double-blind, randomised, placebo-
controlled trial investigated the role of bosentan in 
the reduction of new DUs in 122 patients with SSc 
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allowed, and randomised treatment was administered in addi-
tion to the usual, stable (over the previous month) treatment for 
Raynaud’s phenomenon. Patients who required parenteral, oral 
or inhaled prostanoid treatment during the study were ﬁ  rst dis-
continued from study treatment. Use of glibenclamide, ﬂ  ucon-
azole, calcineurin inhibitors or ciclosporin A was not allowed 
due to potential drug interactions.   
  Outcomes 
  The two primary end points were (1) the mean number of new 
DUs per patient assessed by the investigator up to week 24 
and (2) the time to healing of the cardinal ulcer up to week 
24 in patients with cardinal ulcer healing maintained for 12 or 
more weeks. Healing was deﬁ  ned as complete epithelialisa-
tion, regardless of residual pain. Maintenance of cardinal ulcer 
healing required no recurrence at or contiguous to the original 
location at week 24 (if healing occurred before or at week 12) 
or during 12 weeks of observation with permissible extension 
of the treatment period (if healing occurred after week 12). To 
verify that the effect of treatment would not vary substantially 
across relevant baseline subgroups, the number of new DUs up 
to week 24 was additionally analysed in subgroups based on 
predeﬁ  ned baseline factors associated with disease severity. 
  Secondary and exploratory end points included: (1) reduction 
of new DUs and overall DU number (proportions of patients 
with no new DUs and with each number of new DUs up to 
week 24, time to onset of each number of new DUs up to week 
24 and change from baseline to week 24 in total number of all 
DUs), (2) healing (time to healing of all baseline DUs and of all 
new DUs through week 24, and proportions of patients with 
healing of all DUs by the end of week 24) and (3) pain and dis-
ability parameters (changes from baseline to week 24: in pain 
of the cardinal ulcer and overall hand pain assessed on visual 
analogue scales; hand disability index (an averaged score from 
the three Health Assessment Questionnaire (HAQ) domains 
of dressing/grooming, grip and hygiene); and HAQ disability 
index    18        19   ). 
  Post hoc analyses included: (1) the number of new DUs 
up to week 12 in the overall patient population and in sub-
groups deﬁ  ned by randomisation month (October–February or 
autumn–winter and March–September or spring–summer) and 
(2) number of new DUs, time to each successive new DU and 
total number of DUs through week 24 in subgroups deﬁ  ned by 
the number of DUs at baseline (<4 and ≥4). 
  Patients were evaluated at randomisation/baseline and every 
4 weeks during treatment (or premature withdrawal, week 24 
and, if applicable, 12 weeks after healing of the cardinal ulcer), 
with DUs assessed at each study visit. Safety was continually 
monitored.   
  Statistical  methods 
  Efﬁ  cacy analyses were performed on all treated patients using 
SAS software (SAS Institute, Cary, North Carolina, USA). 
Means±SEs are presented for numerical variables and Kaplan–
Meier estimates for time-to-event variables. Treatment effects 
for the primary end points were evaluated using the Pitman 
permutation (new DUs) and log-rank test with asymptotic 
approximation (time to healing of the cardinal ulcer). Missing 
data on new DUs were imputed using extrapolation, with the 
incidence rate of new DUs at the last assessment corrected for 
the missing time period. The worst of either the calculated num-
ber or observed values at week 24 was used for patients who 
prematurely discontinued study treatment. Patients with no 
and a history of DUs within the previous year.    16    After 16 weeks 
of treatment, patients receiving bosentan had a 48% reduction 
in the mean number of new DUs compared with placebo (1.4 
vs 2.7 new ulcers; p=0.0083), but there were no differences 
between treatments in end points assessing DU healing in the 
63% of patients with active DUs at baseline. 
  The present study (RAPIDS-2, for ‘RAndomized, double-
blind, Placebo-controlled study with bosentan on healing and 
prevention of Ischemic Digital ulcers in patients with systemic 
Sclerosis’) was designed to further investigate the effects of 
bosentan as a treatment for DUs secondary to SSc over a 24-week 
treatment period in a larger population of patients, all of whom 
had active DUs at study entry. The primary objectives were to 
evaluate the effect of bosentan on the reduction of new DUs and 
healing of DUs in patients with SSc. Secondary objectives were 
to evaluate the effect of bosentan on pain and disability, as well 
as its tolerability and safety in these patients.   
  PATIENTS  AND  METHODS 
  Study  design 
  This double-blind, randomised, parallel-group, placebo-
  controlled study consisted of a ≤2-week screening period, a 
24-week treatment period and an 8-week post-treatment fol-
low-up period. The study was approved by local ethics commit-
tees and conducted in accordance with the amended Declaration 
of Helsinki. All patients gave written informed consent.   
  Settings  and  participants 
  The study was conducted from October 2003 to May 2005 at 41 
centres in Europe and North America. Recruited patients were 
≥18 years old, with SSc as deﬁ  ned by the preliminary classiﬁ  ca-
tion criteria of the American College of Rheumatology (ACR)    17    
and at least one active DU (onset between 1 week and 3 months 
prior to randomisation) that was selected by the investigator and 
termed the ‘cardinal ulcer’ (painful area, ≥2 mm in diameter with 
visible depth and loss of dermis, amenable to healing and in a 
location judged compatible with a vascular aetiology, speciﬁ  ed 
by protocol as volar surface of the digit distal to the proximal 
interphalangeal digital crease). 
  Patients were excluded if they had received intravenous pros-
tanoids within the previous 3 months, had used phosphodi-
esterase inhibitors other than for intermittent treatment of male 
erectile dysfunction, or had received inhaled or oral prostanoids 
or injected botulinum toxin in an affected ﬁ  nger within 1 month. 
Patients were also excluded if they received systemic antibiotics 
to treat infected DUs within 2 weeks prior to randomisation. 
Also excluded were patients with body weight <40 kg, severe 
PAH (WHO class III/IV), moderate to severe hepatic impairment 
or serum aminotransferase levels >3 times the upper limit of 
the normal range (ULN). Contraceptive measures and monthly 
pregnancy testing were required during and for 3 months after 
the end of study treatment.   
  Randomisation  and  interventions 
  After screening, patients were randomised to bosentan or 
placebo (1:1 ratio) by sequential allocation of randomisation 
numbers distributed to each centre in blocks of four. Patients 
received bosentan 62.5 mg twice daily for 4 weeks and then 
125 mg twice daily for the remainder of the treatment period or 
matching placebo. The dose could remain at or be decreased to 
the starting dose due to intolerance, with possible subsequent 
increase to the target dose. Concomitant use of systemic anti-
biotics, analgaesics and topical treatments for wound care were 
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    Healing of the cardinal ulcer 
  No difference between bosentan and placebo treatments was 
observed in the time to healing of the cardinal ulcer (HR 0.91 
(95% CI 0.61 to 1.35), p=0.63,   ﬁ  gure 3  ). At week 24, more than 
50% of patients in both groups had healing of the cardinal ulcer 
maintained for at least 12 weeks.       
    Secondary and exploratory end points 
  New  DUs 
  The proportion of patients with no new DUs up to week 24 
was similar with bosentan and placebo (observed in 32/95 
(33.7%) and 26/89 (29.2%) patients, respectively, RR 1.15 
(95% CI 0.75 to 1.77); p=0.53). The proportion of patients 
with one or more new DU was 66.3% (63/95) on bosentan 
compared with 70.8% (63/89) on placebo; the difference in 
observed proportions between treatments was greater in 
patients with multiple new DUs (18.9% vs 29.2% with ≥4, 
10.5% vs 29.8% with ≥5, etc;   ﬁ  gure 4  ). The maximum num-
ber of new DUs per patient was 10 on bosentan and 16 on 
placebo. Time-to-event analyses up to week 24 indicated an 
increasing reduction in risk with bosentan compared with pla-
cebo for the appearance of each successive new DU, with a 
HR of 0.45 (95% CI 0.21 to 0.95, p=0.03) for the ﬁ  fth new DU. 
However, the mean total number of DUs (baseline and new) 
per patient decreased to a similar extent in the bosentan and 
placebo groups (−1.7. (95% CI −2.3 to −1.0) and −1.5 (−2.3 to 
−0.7) DUs, respectively; p=0.76).     
  DU  healing 
  No treatment effects were observed in the times to healing 
up to week 24 for all baseline DUs (HR 0.94 (95% CI 0.65 to 
1.37), p=0.74) or of all new DUs (HR 1.40 (0.78 to 2.51), p=0.26). 
Healing of all DUs (baseline and new combined) at week 24 
was observed in 35/95 (36.8%) and 35/89 (39.3%) of patients 
on bosentan and placebo, respectively (RR 0.94 (95% CI 0.65 to 
1.35), p=0.76).   
valid assessment post baseline (three patients on bosentan, one 
on placebo) were excluded from the main analysis. Treatment 
effects for new DUs in predeﬁ  ned subgroups were presented as 
point estimates and 95% two-sided CIs. 
  For exploratory purposes, statistical tests of treatment dif-
ference were provided for planned secondary/exploratory and 
unplanned post hoc efﬁ  cacy analyses and included the Pitman 
permutation (for changes from baseline), the Fisher exact test 
(for proportions) and the log-rank test (for times to event), each 
performed without correction for multiple testing. Placebo-
corrected changes from baseline, RR and HRs from Cox mod-
elling were each reported with 95% CIs where appropriate. 
Safety and baseline data were summarised descriptively, with 
no statistical testing planned or given.     
  RESULTS 
  The two treatment groups were well matched with respect 
to demographic features, baseline disease characteristics and 
concomitant treatment for DUs at baseline (  table 1  ). All 188 
randomised patients received study treatment, with mean expo-
sures of 22.7±0.9 and 24.5±0.9 weeks in the bosentan and pla-
cebo groups, respectively. The treatment period was completed 
by 75/98 (76.5%) and 73/90 (81.1%) patients, respectively 
  (  ﬁ  gure 1  ), with 9.2% and 7.8%, respectively, discontinued due 
to an adverse event.   
  Primary  end  points 
  New  DUs 
  After 24 weeks of bosentan treatment there was a 30% reduc-
tion in the occurrence of new DUs compared with placebo in the 
study population (1.9 (95% CI 1.4 to 2.3) vs 2.7 (2.0 to 3.4) new 
DUs, p=0.0351,   ﬁ  gure 2  ). Fewer new DUs were observed with 
bosentan than placebo in all subgroups except among current 
smokers (  table 2  , subgroup analyses). This included subgroups 
of limited and diffuse SSc, with no difference between the two 
subgroups in the treatment effect (overlapping 95% CIs).     
  Table  1         Demographics and baseline characteristics of the study population   
 Characteristic   Placebo  (n=90)   Bosentan  (n=98) 
Men/women, % of patients 20/80 22/78
Age in years, mean (SD) 50.7 (12.0) 48.4 (12.9)
Weight in kg, mean (SD) 66.5 (15.8) 64.7 (13.6)
Caucasian/black/other,* % of patients 83/6/11 87/7/6
Smoking status,† % of patients
 Never/previous/current 56/23/22 64/23/13
SSc characteristics
  Limited/diffuse,‡ % of patients 58/42 60/40
  Time from diagnosis of scleroderma to randomisation in years, mean (SD)   8.7 (7.7)   8.7 (8.4)
DU characteristics
  Number at baseline, mean (SD)   3.6 (3.3)   3.7 (4.4)
  Time from ﬁ  rst occurrence of DUs to randomisation in years,† mean (SD)   6.4 (7.1)   7.4 (8.7)
Selected concomitant medication at baseline, % of patients
  Calcium channel blockers 56 50
  Anti-inﬂ  ammatory and antirheumatic products 37 40
 ACE  inhibitors 14 16
 Peripheral  vasodilators§ 10 13
  Angiotensin II receptor blockers   9   8
  Phosphodiesterase inhibitor (sildenaﬁ  l)  3  3
      *Other races included Asian, Hispanic, Indian, Native American and mixed. 
  †Smoking status was available for 88 and 94 patients in the placebo and bosentan groups, respectively, and the time from ﬁ  rst 
occurrence of DUs to randomisation for 89 and 98 patients, respectively. 
  ‡Limited=skin thickening only distal to the elbows and knees. Diffuse=skin thickening proximal to the elbows or knees or affecting 
the trunk. 
  §As deﬁ  ned by the WHO Drug Dictionary and included pentoxifylline, buﬂ  omedil, ginkgo tree leaves extract and ginkgo biloba. 
  ACE, angiotensin-converting enzyme; DU, digital ulcer; SSc, systemic sclerosis.     
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CI −0.15 to 0.08), p=0.51 and −0.04 (−0.20 to 0.12), p=0.62, 
respectively).   
    Post hoc analyses of new DUs 
  In unplanned post hoc analyses in subgroups deﬁ  ned by the 
number of DUs at baseline, the mean treatment effect with 
bosentan was −2.1 (95% CI −3.8 to −0.4) new DUs (p=0.02) 
in patients with at least four DUs at baseline and −0.3 (−1.1 to 
  Pain  and  disability 
  Patient-rated measures of overall hand pain and pain of the 
cardinal ulcer, as assessed by visual analogue scales, showed 
no differential treatment effect in pain at week 24 (mean treat-
ment effects of −1.7 (95% CI −11.4 to 7.9), p=0.73 and −1.6 
(−11.5 to 8.3), p=0.75, respectively). The changes from baseline 
in the HAQ disability index and hand disability index at week 
24 were also similar in both treatment groups (−0.04 (95% 
  Table  2         Number of new DUs up to week 24 in predeﬁ  ned and post hoc subgroups of patients   
 
  Number of new DUs 
 Treatment  effect   p  Value*   n   Placebo   n   Bosentan 
Planned subgroup analyses
 SSc  classiﬁ   cation:
  Diffuse 37 2.7 (1.7 to 3.7) 37 2.1 (1.4 to 2.9) −0.6 (−1.8 to 0.6) 0.35
  Limited 52 2.7 (1.7 to 3.7) 59 1.7 (1.1 to 2.2) −1.0 (−2.1 to 0.0) 0.06
  Time from diagnosis of DU to randomisation:
  ≤5 years 49 2.7 (1.7 to 3.8) 54 1.7 (1.2 to 2.2) −1.0 (−2.2 to 0.1) 0.07
  >5 years 39 2.7 (1.9 to 3.6) 41 2.1 (1.2 to 2.9) −0.7 (−1.8 to 0.5) 0.26
  Systemic antibiotics for DU:
  Yes 11 5.0 (1.4 to 8.6) 16 2.6 (1.1 to 4.0) −2.5 (−5.7 to 0.8) 0.14
  No 77 2.4 (1.8 to 3.0) 76 1.7 (1.2 to 2.2) −0.7 (−1.5 to 0.1) 0.07
  Local treatment for DU:
  Yes 24 2.8 (1.7 to 3.9) 33 2.1 (1.3 to 2.9) −0.7 (−2.0 to 0.6) 0.28
  No 64 2.7 (1.8 to 3.6) 61 1.8 (1.2 to 2.3) −0.9 (−2.0 to 0.1) 0.07
  Dose adjustment of treatment for Raynaud’s phenomenon:
  Yes 19 3.5 (1.8 to 5.3) 22 1.8 (0.9 to 2.6) −1.8 (−3.6 to 0.1) 0.05
  No 69 2.5 (1.8 to 3.3) 72 1.9 (1.4 to 2.4) −0.6 (−1.5 to 0.3) 0.20
  Smoking habit at baseline:
  Never 49 3.0 (2.1 to 4.0) 58 2.2 (1.6 to 2.9) −0.8 (−1.9 to 0.3) 0.15
  Previous 20 3.3 (1.3 to 5.3) 22 1.3 (0.7 to 2.0) −2.0 (−4.0 to −0.1) 0.04
  Current 19 1.3 (0.6 to 2.0) 12 1.5 (0.4 to 2.6) 0.2 (−1.0 to 1.3) 0.82
Post hoc subgroup analyses
  Number DUs at baseline:
  <4 60 1.9 (1.3 to 2.5) 59 1.6 (1.1 to 2.0) −0.3 (−1.1 to 0.4) 0.39
  ≥4 29 4.4 (2.8 to 6.1) 36 2.4 (1.5 to 3.2) −2.1 (−3.8 to −0.4) 0.02
 Randomisation  month:†
  October 2003 to February 2004 37 1.3 (0.7 to 1.9) 29 0.7 (0.4 to 1.0) −0.6 (−1.3 to 0.1) 0.12
  March 2004 to September 2004 52 1.3 (0.7 to 1.8) 64 0.8 (0.5 to 1.2) −0.4 (−1.0 to 0.2) 0.20
      Data are mean (95% CIs). 
  *Exploratory p value determined using the Pitman permutation. 
  †Analysis conﬁ  ned to the ﬁ  rst 12 weeks of treatment to avoid overlap of seasons. 
  DU, digital ulcer; SSc, systemic sclerosis.     
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  Figure  1      Study  ﬂ   ow  diagram.    
  Figure  2         Mean number of new digital ulcers in the study population 
up to weeks 12 and 24. p Values were determined using the Pitman 
permutation. Two patients on bosentan had no week 12 assessment.       
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serious event (pneumonia) reported for more than one patient 
on bosentan. One patient on placebo died from acute respira-
tory distress syndrome during the post-treatment follow-up. 
The proportions of patients experiencing at least one adverse 
event were similar in both treatment groups (  table 4  ). Adverse 
events occurring in more patients on bosentan than placebo 
included peripheral oedema (18.8% vs 4.4%) and events denot-
ing elevated aminotransferases (12.5% vs 2.2%). These adverse 
events resulted in premature discontinuation of bosentan treat-
ment in 2.1% and 5.2% of patients, respectively (vs none on 
placebo). Overall, adverse events led to the discontinuation of 
study treatment in 15.6% of patients on bosentan and 12.2% 
on placebo. Laboratory tests identiﬁ  ed increased aminotrans-
ferases to >3×ULN in 10/95 (10.5%) patients on bosentan 
(which included one patient with an elevation to >8×ULN) and 
1/88 (1.1%) patients on placebo. In all cases on bosentan, ele-
vated aminotransferases resolved during continued treatment, 
after a decrease in dose, or following temporary or permanent 
treatment discontinuation.     
  DISCUSSION 
  In this randomised, placebo-controlled trial, bosentan treat-
ment was associated with a 30% reduction in the number 
of new DUs over the 24-week treatment period but did not 
result in a treatment effect on healing of the cardinal ulcer. The 
reduction of new DUs was more pronounced among patients 
with multiple DUs; large numbers of new DUs were less likely 
to occur, and the appearance of each successive new DU was 
delayed in patients on bosentan compared with those on pla-
cebo. Based on post hoc analyses, the reduction of new DUs 
appeared to be greater in patients with at least four DUs at 
baseline. 
  The mean total number of DUs per patient at week 24 was 
similar in the two treatment groups, and no treatment effects 
were observed in the other measures of healing or patient-rated 
measures of pain and disability used. This is the second ran-
domised placebo-controlled trial to show a reduction in the 
number of new DUs in susceptible patients with SSc treated 
with bosentan. Consistent with the ﬁ  rst trial, the observed treat-
ment effect was greater in patients with multiple DUs, while 
there was no effect on healing parameters.    16    
0.4) new DUs (p=0.39) in patients with less than four DUs at 
baseline (  table 2  ). In both subgroups, the estimated proportion 
of patients without each subsequent new DU was larger in the 
bosentan than placebo group except the ﬁ  rst new DU (  table 3  ), 
and the difference between treatment groups was larger among 
patients with at least four new DUs than in those with fewer 
than four new DUs. No difference between treatments was 
observed in the mean total number of DUs (baseline plus new) 
per patient among patients with at least four DUs at baseline 
(−3.4 (95% CI −4.8 to −1.9) on bosentan and −3.6 (−5.4 to −1.7) 
DUs on placebo) and those with fewer than four DUs at baseline 
(−0.6 (−1.0 to −0.2) and −0.5 (−1.1 to 0.1) DUs, respectively). 
  An analysis of subgroups based on randomisation month 
(October–February, March–September) conﬁ   ned to the ﬁ  rst 
12 weeks of treatment (to avoid overlapping time periods) found 
no effect of season on the treatment effect (  table 2  ).   
  Safety  and  tolerability 
  Serious adverse events occurred in 9.4% and 16.7% of patients 
on bosentan and placebo, respectively (  table 4  ), with only one 
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  Figure  3         Kaplan–Meier estimates of time to complete healing of the cardinal ulcer.       
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on prevention of new ulcers must examine if patient beneﬁ  t 
would result, as opposed to the design adopted in the present 
study. 
  The increased incidence of elevated aminotransferases with 
bosentan in this and other studies reinforces the need for con-
tinual monitoring of liver function with this treatment. The 
incidence, severity and resolution of these abnormalities in 
this study were similar to previous reports.    13    The increased 
incidence of peripheral oedema with bosentan was not previ-
ously reported in patients with DUs    16    but has been seen in other 
patient populations.    20    
  This was a large and complex controlled trial, but there are 
limitations to the data interpretation. The deﬁ  nition of an active 
DU used in this trial may not match criteria used in other centres. 
The clinical utility of this promising approach to treatment may 
be challenged. In a patient encountered with a single DU, initia-
tion of bosentan would not be expected to facilitate healing, and 
at least 66% of all bosentan-treated subjects would develop at 
least one additional DU over 6 months of follow-up. However, 
in those patients presenting with multiple DUs (at least four), 
the effect of bosentan treatment on the reduction of new DUs 
offers greater potential beneﬁ  t. Major outcomes including hos-
pitalisations for infection or need for surgical amputation occur 
too infrequently to serve as outcome measures in trials of this 
sort, but it seems reasonable to surmise that reduced occurrence 
of DUs would ultimately reduce the risk of same in an appropri-
ate population. 
  In conclusion, two randomised trials have shown that bosen-
tan treatment reduces the occurrence of new DUs compared 
with placebo in patients with SSc but has no effect on DU heal-
ing. Bosentan was well tolerated and may be a useful adjunct in 
the management of patients with SSc and recurrent DUs.             
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  The reduction of new DUs without effect on healing in 
bosentan-treated patients did not translate into a smaller ulcer 
burden, as was seen in the previous study.    16    In this study, 
similar reductions in the overall number of DUs (present at 
baseline and/or new) occurred in both groups. The difference 
between studies could not be explained by a seasonal effect 
on the appearance of new DUs due to the different enrolment 
periods (October–September vs October–February in the ﬁ  rst 
study). Raynaud’s phenomenon is thought to be more severe 
and new DUs more frequent during the autumn and winter, 
but the numbers of new DUs in autumn/winter and spring/
summer randomisation subgroups were nearly identical. The 
patient populations for the two studies appeared similar except 
that in the earlier study, 38% of patients had no active DU at 
baseline.    16    Patients in the earlier study had fewer DUs to heal, 
perhaps giving more weight to prevention in the reduction of 
overall ulcer burden. 
  The reduction of new DUs with bosentan also did not trans-
late into measurable decreases in pain or disability compared 
with placebo. Explanations could include (1) the expected 
result, given no differences in total number of DUs between 
treatment groups, (2) a lack of sensitivity to change and dis-
criminative value in the current instruments used to assess 
hand function in SSc and (3) bosentan treatment does not 
improve pain and disability in spite of the reduction of new 
DUs. Improvement in hand function was seen in the previ-
ous study.    16    A clear picture of the overall beneﬁ  ts of treatment 
on patient well-being remains elusive, as remaining DUs and 
the underlying healing rate may confound overall assessments. 
In this study, both groups had an equal opportunity for ben-
eﬁ  t so it may be inferred that in the future, a long-term study 
  Table  3         Kaplan–Meier estimates of patients without subsequent new DUs at week 20 by number of DUs at 
baseline  
  Event-free rate (%) 
  <4 DUs at baseline    ≥4 DUs at baseline 
 Placebo  (n=61)   Bosentan  (n=61)   Placebo  (n=29)   Bosentan  (n=37) 
First new DU 45.8 47.7 24.1 23.4
Second new DU 66.5 70.1 44.8 57.3
Third new DU 84.2 85.0 55.2 75.3
Fourth new DU 84.0 96.1 58.6 84.2
Fifth new DU 92.9 98.0 72.4 90.6
   DU,  digital  ulcer.   
  Table  4         Summary of adverse events occurring during and up to 1 day 
after the end of study treatment   
  Adverse event, n (%)   Placebo  (n=90)   Bosentan  (n=96) 
All patients with ≥1 adverse event 76 (84.4) 83 (86.5)
Peripheral oedema 4 (4.4) 18 (18.8)
Elevated aminotransferases* 2 (2.2) 12 (12.5)
Arthralgia 6 (6.7) 10 (10.4)
Headache 11 (12.2) 9 (9.4)
Infected skin ulcer 6 (6.7) 9 (9.4)
Upper respiratory tract infection 7 (7.8) 8 (8.3)
Diarrhoea 8 (8.9) 6 (6.3)
Pain in extremity 4 (4.4) 6 (6.3)
Nausea 11 (12.2) 5 (5.2)
Skin ulcer/disease progression 7 (7.8) 5 (5.2)
Urinary tract infection 3 (3.3) 5 (5.2)
Dermatitis 2 (2.2) 5 (5.2)
Other† 70 (77.8) 78 (81.3)
All patients with ≥1 serious adverse event 15 (16.7) 9 (9.4)
      *Reported by investigators as alanine aminotransferase increased, aspartate 
aminotransferase increased and liver function test abnormal. 
  †Includes all adverse events with an incidence on bosentan <5%.     
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